Azora Therapeutics, Inc. (AZR)

Market Cap	8.27M
Revenue (ttm)	n/a
Net Income	n/a
EPS	n/a
Shares Out	2.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,822
Open	4.710
Previous Close	4.880
Day's Range	3.020 - 4.940
52-Week Range	1.310 - 9.223
Beta	1.50
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AZR

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon‑targeted aryl hydrocarbon receptor (AhR) agonist to enable localized activation with limited systemic exposure in development for ulcerative colitis. Azora Therapeutics, Inc. was formerly known as Meya Pharmaceuticals, Inc. and changed its name to Azora Therapeutics, In...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: Nasdaq
• Ticker Symbol: AZR
• Website: https://www.azoratherapeutics.com

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 30, 2026

Data Sources Report a data error